

OLPRUVA - (2000MG, 3000MG, 4000MG, 5000MG, 6000MG, 6670MG, 500MG, 1000MG Packet ; For Suspension)

| | | | |
|------------------------------|--|-----------------------------|---------------------|
| Generic Name | SODIUM PHENYL BUTYRATE | Innovator | Acer |
| Dosage | 2000MG, 3000MG, 4000MG, 5000MG, 6000MG, 6670MG, 500MG, 1000MG Packet ; For Suspension | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | None | Known Para IV Filers | None |
| Other ANDA developers | None | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | OLPRUVA is a nitrogen-binding agent indicated as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of adult and pediatric patients weighing 20 kg or greater and with a body surface area (BSA) of 1.2 m ² or greater, with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.